Livzon Wins NMPA Nod to Test NS-041 Tablet for Depression in China

Livzon Pharmaceutical Group ( (HK:1513) ) has provided an announcement.

Livzon Pharmaceutical Group announced that its subsidiary has received approval from China’s National Medical Products Administration to initiate clinical trials of NS-041 Tablet for an additional indication in the treatment of depression. NS-041 is a novel, highly selective KCNQ2/3 agonist and currently the only drug of its class in China cleared for clinical studies in both epilepsy and depression, with a Phase II epilepsy trial already under way. Preclinical data indicate favorable antidepressant effects and high target selectivity without observed ocular toxicity, and Livzon holds exclusive Greater China rights under a 2024 licensing deal with NeuShen Therapeutics. The move underscores Livzon’s push into innovative neuropsychiatric therapies and, given the lack of marketed next-generation KCNQ2/3-targeting drugs in China, could strengthen its competitive position if clinical results prove positive.

The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.

More about Livzon Pharmaceutical Group

Livzon Pharmaceutical Group Inc., through its wholly owned subsidiary Livzon Group Livzon Pharmaceutical Factory, operates in China’s pharmaceutical industry with a focus on innovative chemical drugs. The company is developing novel treatments for neuropsychiatric disorders, including epilepsy and depression, and holds exclusive Greater China rights to NS-041 Tablet, an in-licensed Class 1 chemical drug targeting KCNQ2/3 channels.

YTD Price Performance: 10.77%

Average Trading Volume: 784,843

Technical Sentiment Signal: Hold

Current Market Cap: HK$32.14B

For a thorough assessment of 1513 stock, go to TipRanks’ Stock Analysis page.